AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guarnieri, G. F.
Right arrow Articles by Campanacci, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guarnieri, G. F.
Right arrow Articles by Campanacci, L.
Agricola
Right arrow Articles by Guarnieri, G. F.
Right arrow Articles by Campanacci, L.

American Journal of Clinical Nutrition, Vol 33, 1489-1492, Copyright © 1980 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis

GF Guarnieri, F Ranieri, G Toigo, A Vasile, M Ciman, V Rizzoli, M Moracchiello and L Campanacci

Hypertriglyceridemia is often present in chronically uremic patients treated with maintenance hemodialysis and has been considered a risk factor in the accelerated development of atheroma. Muscle carnitine content is low in hemodialyzed patients. This abnormality may help to explain the myopathy and cardiomyopathy often observed in these subjects. In addition, carnitine might play a role in the hypertriglyceridemia in renal failure. Carnitine, which is necessary for fatty acid oxidation, has been recently reported to lower serum triglycerides in patients with type IV hyperlipoproteinemia. Carnitine was administered intravenously three times weekly at the end of hemodialysis in eight patients. Carnitine was given in 0.5 g doses for 8 weeks and then in 1.0 g doses for 6 additional weeks. There was a significant decrease in serum triglycerides at the end of treatment. In contrast, serum lipids in eight hemodialysis patients receiving placebo did not change significantly. Carnitine administration does not cause any side effect except some euphoria. These results suggest that carnitine may be effective in the treatment of hypertriglyceridemia in dialysis patients.


This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
B. Schreiber
Levocarnitine and Dialysis: A Review
Nutr Clin Pract, April 1, 2005; 20(2): 218 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J.-M. Hurot, M. Cucherat, M. Haugh, and D. Fouque
Effects of L-Carnitine Supplementation in Maintenance Hemodialysis Patients: A Systematic Review
J. Am. Soc. Nephrol., March 1, 2002; 13(3): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zhu, M. C. Jong, K. A. Frazer, E. Gong, R. M. Krauss, J.-F. Cheng, D. Boffelli, and E. M. Rubin
Genomic interval engineering of mice identifies a novel modulator of triglyceride production
PNAS, February 1, 2000; 97(3): 1137 - 1142.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by The American Society for Nutrition